Please login to the form below

Not currently logged in
Email:
Password:

MSD strikes vernakalant deal with Astellas

US-based pharmaceutical company MSD has acquired the rights for heart drug vernakalant from Astellas

MSD (known as Merck in the US and Canada) has acquired the exclusive rights to develop and commercialise the investigational intravenous formulation of atrial fibrillation drug vernakalant in Canada, Mexico and the US from Astellas.

MSD will pay Astellas an undisclosed upfront fee. In addition, Astellas will be eligible for milestone payments associated with development and regulatory approval, as well as sales thresholds achieved in Canada, Mexico and the US.

Masao Yoshida, president and chief executive of Astellas US, said: "In reviewing the priorities of our North American development programmes, Astellas has decided to divest its rights for vernakalant to Merck."

In October 2003, Astellas US was granted an exclusive licence to develop and commercialise vernakalant iv in Canada, Mexico and the US by Cardiome Pharma Corp. In April 2009, MSD, through a subsidiary, was granted exclusive rights to vernakalant iv outside of Canada, Mexico and the US for rapid conversion of acute atrial fibrillation to normal heart rhythm.

Vernakalant is approved in more than 10 European countries.

27th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics